Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions

Quarterly Journal of Nuclear Medicine

Volumn 45, Issue 1, 2001, Pages 27-37

  Savelli, G ^a   Maffioli, L ^a   Maccauro, M ^a   De Deckere, E ^a   Bombardieri, E ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Bone neoplasms, diagnosis; Bone neoplasms, radionuclide imaging; Bone neoplasms, secondary; Tomography, emission computed, single photon

Indexed keywords

RADIOISOTOPE;

ARTICLE; BONE LESION; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; BREAST CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FUNCTIONAL ASSESSMENT; HUMAN; IMAGING SYSTEM; LUMBAR SPINE; LUNG CANCER; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PROGNOSIS; PROSTATE CANCER; RADIOISOTOPE DIAGNOSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SPINAL NEOPLASMS; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034954678     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Detection and clinical importance of micrometastases disease
2. Function of vertebral veins and their role in spread and metastases
3. Correlation between the prostatic vein and vertebral venous system under various conditions
4. Metastases: Mechanism, pathways, and cases
5. Diagnostic bone scanning in oncology
6. Scintigraphy of bone metastases
7. Vertebral compression fractures: Distinction between benign and malignant causes with MR imaging
8. 99mTc-methylenediphosphonate scintigraphy in the examination of patients with suspected skeletal metastases
9. Magnetic resonance imaging versus radionuclide scintigraphy for screening in bone metastases
10. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system
11. Total-body echo-planar MR imaging in the staging of breast cancer: Comparison with conventional methods: Early experience
12. Detection of bone metastases in breast cancer by 18-FDG-PET: Differing metabolic activity in osteoblastic and osteolytic lesions
13. Accuracy of whole body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma
14. Comparison of bone single-photon emission tomography and planar imaging in detection of vertebral metastases in patients with back pain
15. Does bone SPECT actually have lower sensitivity for detecting vertebral metastases than MRI?
16. The role of bone SPET study in diagnosis of single vertebral metastase
17. The clinical course of bone metastases from breast cancer
18. Secondary malignant bone disease
19. Skeletal scintigraphy in breast cancer management
20. Value of pre-treatment and follow-up; skeletal scintigraphy in operable breast cancer
21. CA 15-3 and bone scintigraphy in the follow-up of breast cancer
22. Single determination of CA15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer
23. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy
24. Role of bone scan in breast cancer follow-up
25. Breast cancer with bone only metastasis. Visceral metastases-free rate in relation to anatomic distribution of bone metastases
26. Clinical course and prognostic factors following bone recurrence from breast cancer
27. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomised trial. National Research Council Project on Breast Cancer Follow Up
28. In multicentre randomised control trial. The GIVIO investigators
29. Skeletal metastases from breast cancer: Imaging with nuclear medicine
30. The bone scan and breast cancer
31. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
32. Should biphosphonates be standard therapy for bone pain?
33. Reduction in new metastases in breast cancer with adjuvant chlorinate treatment
34. The British Association of Surgical Oncology Guidelines for surgeons in the management of symptomatic breast disease in the UK (1998 revision)
35. Orthopedic surgical management of skeletal complications of malignancy
36. Radioisotope-guided surgical biopsy of suspected osseous metastases
37. Assessment of response to therapy in advanced breast cancer: A project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland
38. Bone scan flare predicts successful systemic therapy for bone metastases
39. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer
40. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer
41. Bone scan and prostate cancer
42. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate
43. Serial bone scanning in the evaluation of stage and clinical course in carcinoma of the prostate
44. Prostatic specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
45. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate
46. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
47. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Specific antigen is superior to all other clinical parameters
48. Imaging of patients with stage D prostate carcinoma
49. Serum prostate specific antigen as a serum marker of bone metastasis in patients with prostate cancer
50. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer
51. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer
52. Prostate-specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status?
53. The value of baseline bone scan in patients with newly diagnosed prostate cancer
54. Do bone scans predict the prognosis in prostate cancer? A report of the EORTC protocol 30762
55. The impact of current staging procedures in assessing disease extent of prostatic adenocarcinoma
56. The role of routine follow-up bone scan after definitive therapy of localised prostatic cancer
57. PSA and bone scintigraphy
58. Extent of disease based on initial bone scan: Important prognostic predictor for patients with metastatic prostatic cancer
59. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan
60. Metastases in carcinoma: Analysis of 1000 autopsied cases
61. How omonous is an abnormal bone scan in bronchogenic carcinoma?
62. Radioisotope scanning in the initial staging of bronchogenic carcinoma
63. Sequential scintigraphic staging of small cell carcinoma
64. Pretreatment evaluation of non-small cell lung cancer
65. Bone metastases. The clinical problem
66. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer
67. Suspected non-small cell lung cancer: Incidence of occult metastases and effectiveness of imaging for detection. Pilot Study
68. Cost effective analysis of prenephrectomy radioisotope scans in renal cell carcinoma
69. Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan
70. Value of routine radionuclide bone scans in renal cell carcinoma
71. Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma
72. Lymphoma of the skeleton: Scintigrafic evaluation
73. Bone scans in bone metastases from functioning thyroid carcinoma
74. Value of combined technetium-99m hydroxy methylene diphosphonate and thallium-201 imaging in detecting bone metastases from thyroid carcinoma
75. The role of TI-201 total body scintigraphy in the follow up of thyroid carcinoma
76. Follow-up study of postoperative patients with thyroid cancer by thallium-201 scintigraphy and serum thyroglobulin measurement
77. Nasopharyngeal carcinoma: Patterns of skeletal metastases
78. Detection of metastases from head and neck cancers
79. Role of bone scanning in detection of subclinical bone metastases in nasopharyngeal carcinoma
80. Do metastases in vertebrae begin in the body or the pedicles?
81. Arterial changes in the human vertebral body associated with aging
82. A profile of metastatic carcinoma of the spine
83. Issues concerning the rule of chemotherapy and hormonal therapy for bone metastases from breast carcinoma
84. An evaluation of the potential cost-reductions resulting from the use of clodronate in the treatment of metastatic carcinomas of the breast
85. Red-yellow marrow conversion: Its effect on the location of some solitary bone lesions
86. The arterial anatomy of the developing human vertebral body
87. Metastases and arteries of the vertebral body